Some of functionality may not work while you disabled JavaScript. Enable JavaScript for better User Exprience.
Access here alternative investment news about Ainsling Capital Raises $280m For Latest Life Sciences Fund
Private Equity

Ainsling Capital Raises $280m For Latest Life Sciences Fund

by finalternatives.com posted 1year ago 166 views
New York-based life sciences private equity company Aisling Capital has raised $280 million capital commitments for its latest fund to focus on bringing breakthrough medical treatments to market. With the new fund, Aisling will assist companies developing therapeutics to complete their clinical studies, navigate approval and ultimately reach commercialization, the company said. “Today, every biotech company must develop treatments that generate significant upside for patient care through profound impact on disease, fewer side effects, and a shift away from toxic therapies toward a personalized approach,” said Steve Elms, co-managing partner of Aisling Capital, in a statement.

In this article